Literature DB >> 26976989

Prognostic Significance of the Preoperative Ratio of C-Reactive Protein to Albumin in Patients with Colorectal Cancer.

Masatsune Shibutani1, Kiyoshi Maeda2, Hisashi Nagahara2, Yasuhito Iseki2, Tetsuro Ikeya2, Kosei Hirakawa2.   

Abstract

BACKGROUND: Inflammation has been reported to play an important role in cancer progression, and several inflammatory markers, such as the neutrophil to lymphocyte ratio (NLR) and modified Glasgow prognostic score (mGPS), have been reported to be prognostic markers. The aim of this retrospective study was to evaluate the prognostic significance of the ratio of C-reactive protein to albumin (CRP/ALB ratio) in patients with colorectal cancer who undergo potentially curative surgery. PATIENTS AND METHODS: A total of 705 patients who underwent potentially curative surgery for colorectal cancer were enrolled. The CRP/ALB ratio was calculated form the preoperative samples by dividing the serum C-reactive protein level by the serum albumin level. We evaluated the correlation between the CRP/ALB ratio and survival. Furthermore, we compared the accuracy of the CRP/ALB ratio as a predictor for survival with the mGPS.
RESULTS: We set 0.0271 as the cut-off value for the CRP/ALB ratio according to a receiver operating characteristic curve analysis. Based on the cut-off value of 0.0271, 347 patients were classified into the low CRP/ALB ratio group and 358 patients were classified into the high CRP/ALB ratio group. The group with high CRP/ALB ratio had significantly worse relapse-free survival (p=0.0003) and cancer-specific survival (p=0.0026) rates than those of the low CRP/ALB ratio group. According to a multivariate analysis, the CRP/ALB ratio was identified as an independent prognostic factor for relapse-free survival (p=0.025) and cancer-specific survival (p=0.045). Moreover, even in a sub-analysis limited to patients with an mGPS of 0, the high CRP/ALB ratio group had significantly worse relapse-free survival (p=0.0015) and cancer-specific survival (p=0.0131) rates than the low CRP/ALB ratio group.
CONCLUSION: The preoperative CRP/ALB ratio is a useful prognostic marker in patients with colorectal cancer who undergo potentially curative surgery. Moreover, the CRP/ALB ratio may be superior to the mGPS for predicting survival. Copyright
© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  C-reactive protein to albumin ratio; Colorectal cancer; prognosis

Mesh:

Substances:

Year:  2016        PMID: 26976989

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  38 in total

1.  Preoperative C-Reactive Protein/Albumin Ratio as a Predictive Factor for Gallbladder Carcinoma.

Authors:  Masashi Utsumi; Hideki Aoki; Seichi Nagahisa; Seitaro Nishimura; Yuta Une; Yuji Kimura; Megumi Watanabe; Fumitaka Taniguchi; Takashi Arata; Koh Katsuda; Kohji Tanakaya
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

2.  Prognostic value of the combination of pre- and postoperative C-reactive protein in colorectal cancer patients.

Authors:  Manabu Yamamoto; Hiroaki Saito; Chihiro Uejima; Akimitsu Tanio; Seigo Takaya; Teruhisa Sakamoto; Soichiro Honjo; Yoshihiko Maeta; Keigo Ashida; Yoshiyuki Fujiwara
Journal:  Surg Today       Date:  2018-06-26       Impact factor: 2.549

3.  [C-reactive protein/albumin ratio as a novel inflammation-based prognostic index for predicting outcomes of patients with colorectal cancer].

Authors:  Ying-Ying Chen; Jia-He Zhang; Wan Zhang; Zi-Ke Yang; Rong-Cheng Luo; Shi-Jun Kang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-05-20

4.  Neutrophil-to-lymphocyte ratio and C-reactive protein-to-albumin ratio as prognostic factors for unresectable advanced or recurrent gastric cancer.

Authors:  Tsutomu Namikawa; Shigeto Shimizu; Keiichiro Yokota; Nobuhisa Tanioka; Masaya Munekage; Sunao Uemura; Hiromichi Maeda; Hiroyuki Kitagawa; Michiya Kobayashi; Kazuhiro Hanazaki
Journal:  Langenbecks Arch Surg       Date:  2021-10-15       Impact factor: 3.445

5.  Combination of C-reactive Protein and Monocyte Count Is a Useful Prognostic Indicator for Patients With Colorectal Cancer.

Authors:  Manabu Yamamoto; Hiroaki Saito; Kazushi Hara; Ken Sugezawa; Chihiro Uejima; Akimitsu Tanio; Yoichiro Tada; Kyoichi Kihara; Teruhisa Sakamoto; Soichiro Honjo; Yoshiyuki Fujiwara
Journal:  In Vivo       Date:  2020 Jan-Feb       Impact factor: 2.155

6.  The C-reactive protein to albumin ratio predicts postoperative complications in oldest-old patients with colorectal cancer.

Authors:  Shintaro Hashimoto; Tetsuro Tominaga; Takashi Nonaka; Kiyoaki Hamada; Masato Araki; Hiroaki Takeshita; Hidetoshi Fukuoka; Hideo Wada; Kazuo To; Hideaki Komatsu; Kenji Tanaka; Terumitsu Sawai; Takeshi Nagayasu
Journal:  Int J Colorectal Dis       Date:  2020-01-02       Impact factor: 2.571

7.  Prognostic Impact of Inflammation-related Biomarkers on Overall Survival of Patients with Inoperable Malignant Pleural Mesothelioma.

Authors:  Takehiro Otoshi; Yuki Kataoka; Sawako Kaku; Reika Iki; Masataka Hirabayashi
Journal:  In Vivo       Date:  2018 Mar-Apr       Impact factor: 2.155

8.  The Combination of Prognostic Nutritional Indicator and Serum Carcinoembryonic Antigen is Useful in Predicting Postoperative Recurrence in Stage II Colorectal Cancer.

Authors:  Chihiro Uejima; Hiroaki Saito; Yoichiro Tada; Akimitsu Tanio; Yuki Murakami; Manabu Yamamoto; Tomoyuki Matsunaga; Yoji Fukumoto; Naruo Tokuyasu; Shuichi Takano; Teruhisa Sakamoto; Soichiro Honjo; Yoshiyuki Fujiwara
Journal:  Yonago Acta Med       Date:  2021-05-20       Impact factor: 1.641

9.  C-reactive protein/albumin ratio predicts survival after curative surgery in elderly patients with colorectal cancer.

Authors:  Koki Tamai; Shu Okamura; Shunichiro Makino; Noriyuki Yamamura; Nariaki Fukuchi; Chikara Ebisui; Akira Inoue; Masahiko Yano
Journal:  Updates Surg       Date:  2021-03-06

10.  The Prognostic Value of New Index (LANR) Composed of Pre-operative Lymphocytes, Albumin, and Neutrophils in Patients With Resectable Colorectal Cancer.

Authors:  Xinjun Liang; Shuang Yao; Ping Lu; Yifei Ma; Hongli Xu; Zhucheng Yin; Junjie Hu; Yanyan Liu; Shaozhong Wei
Journal:  Front Oncol       Date:  2021-05-25       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.